Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TriLink Opens GMP Enzyme Manufacturing Facility in Jupiter, FL | Contract Pharma

What are you searching for?

Sign in
Breaking News

TriLink Opens GMP Enzyme Manufacturing Facility in Jupiter, FL

The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

TriLink, part of Maravai LifeSciences, has opened a GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

The launch addresses a long-standing pain point for RNA therapeutics developers sourcing critical raw materials from multiple vendors: managing different quality systems, timelines, and supply processes can slow development and create manufacturing risk. TriLink is now offering these materials as a coordinated, single-source package designed to simplify development and scale up.

“RNA therapeutics developers need reliable supply partners that can support them from early research through commercial manufacturing. By combining enzyme manufacturing capabilities with TriLink’s existing RNA technologies, we help customers simplify sourcing, reduce supply chain complexity, and accelerate scale-up with greater confidence,” said Chad Decker, SVP Global Sales, TriLink BioTechnologies.

The Jupiter facility was purpose-built for GMP enzyme manufacturing. It features controlled cleanroom environments, validated production processes, and scalable capacity designed to support both clinical-stage programs and commercial supply. Full traceability and quality systems are in place to meet regulatory requirements across major markets.

The facility is already supporting customer programs, with TriLink successfully shipping its first commercial GMP enzyme batch in June 2026.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics